Published in Lab Invest on September 01, 1979
Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest (1988) 1.60
The platelet-independent release of thromboxane A2 by Paf-acether from guinea-pig lungs involves mechanisms distinct from those for leukotriene. Br J Pharmacol (1984) 1.42
Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. Proc Natl Acad Sci U S A (1983) 1.25
Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. Gut (1992) 1.10
The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. Br J Pharmacol (1983) 1.07
Paf-acether synthesis by Helicobacter pylori. Gut (1990) 1.06
Human platelets stimulated by thrombin produce platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when the degrading enzyme acetyl hydrolase is blocked. Biochem J (1985) 1.01
Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation. Br J Pharmacol (1984) 0.95
Platelet activating factor: an inhibitor of neutrophil activation? Clin Exp Immunol (1981) 0.85
Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). Agents Actions (1981) 0.84
Release of a slow-reacting substance from rabbit platelets. J Clin Invest (1981) 0.84
The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation. Agents Actions (1984) 0.83
Gastric secretion of platelet activating factor and precursors in healthy humans: effect of pentagastrin. Gut (1993) 0.81
Platelet release reaction and aggregation induced by canatoxin, a convulsant protein: evidence for the involvement of the platelet lipoxygenase pathway. Br J Pharmacol (1985) 0.80
Platelet serotonin release by human polymorphonuclear leucocytes stimulated by cotton dust bacteria. Clin Exp Immunol (1983) 0.80
Effects of platelet-activating factor on the release of arachidonic acid and prostaglandins by rabbit iris smooth muscle. Inhibition by calcium channel antagonists. Biochem J (1985) 0.79
Acetal phosphatidic acids: novel platelet aggregating agents. Br J Pharmacol (1983) 0.78
Phospholipid biosynthesis in human platelets. The acylation of lyso-platelet-activating factor. Biochem J (1985) 0.78
Biosynthesis of paf-acether. Paf-acether but not leukotriene C4 production is impaired in cultured macrophages. Biochem J (1989) 0.78
Biosynthesis of paf-acether. Activators of protein kinase C stimulate cultured mast cell acetyltransferase without stimulating paf-acether synthesis. Biochem J (1990) 0.78
Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells. Br J Pharmacol (1989) 0.76
Platelet-activating factor: mediator of the third pathway of platelet aggregation? A study in three patients with deficient platelet-activating factor synthesis. J Clin Invest (1987) 0.75
Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med (1972) 5.38
Factors influencing platelet function: adhesion, release, and aggregation. Pharmacol Rev (1970) 4.48
Preparation of suspensions of washed platelets from humans. Br J Haematol (1972) 4.02
Platelet aggregation and release of ADP, serotonin and histamine associated with phagocytosis of antigen-antibody complexes. Proc Soc Exp Biol Med (1965) 2.91
Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol (1980) 2.90
Phyllosilicates on Mars and implications for early martian climate. Nature (2005) 2.66
[Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine]. C R Seances Acad Sci D (1979) 2.53
The role of platelet-activating factor in platelet aggregation. Nature (1979) 2.37
The effect of acetylsalicyclic acid on platelet function. J Exp Med (1968) 2.35
Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest (1999) 2.34
Platelet phagocytosis and aggregation. J Cell Biol (1965) 2.27
Adenosine diphosphate-induced platelet aggregation in suspensions of washed rabbit platelets. Br J Haematol (1970) 2.27
Background and present status of research on platelet-activating factor (PAF-acether). Ann N Y Acad Sci (1981) 2.22
Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol (1979) 2.10
Structural analysis of purified platelet-activating factor by lipases. Nature (1977) 2.09
Carrier detection of Hemophilia B by using a restriction site polymorphism associated with the coagulation Factor IX gene. J Clin Invest (1984) 2.07
Response of platelets to tissue injury. Biochem Pharmacol (1968) 2.01
Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils. Nature (1974) 1.97
Resolution and organization of platelet-rich mural thrombi in carotid arteries of swine. Am J Pathol (1967) 1.91
Release of permeability factors from the blood platelet. Proc Soc Exp Biol Med (1966) 1.86
Human epidermal Langerhans cells cointernalize by receptor-mediated endocytosis "nonclassical" major histocompatibility complex class I molecules (T6 antigens) and class II molecules (HLA-DR antigens). Proc Natl Acad Sci U S A (1987) 1.82
Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med (2001) 1.75
Circulating DNA:anti-DNA complexes in systemic lupus erythematosus. Detection and characterization by ultracentrifugation. J Clin Invest (1979) 1.74
Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol (1975) 1.70
Fibrinogen and ADP-induced platelet aggregation. Blood (1978) 1.70
The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett (1997) 1.70
Genetic screening for hemophilia A (classic hemophilia) with a polymorphic DNA probe. N Engl J Med (1985) 1.67
Deposition of formed elements of blood on the intima and signs of intimal injury in the aorta of rabbit, pig, and man. Lab Invest (1972) 1.63
Controlled clinical trial of homoeopathy in postoperative ileus. Lancet (1988) 1.61
Adenosine diphosphate-induced platelet aggregation and vascular injury in swine and rabbits. Am J Pathol (1970) 1.60
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol (2001) 1.59
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
Release of platelet-activating factor (PAF-acether) from alveolar macrophages by the calcium ionophore A23187 and phagocytosis. Eur J Clin Invest (1980) 1.50
Effect of mouse peritoneal macrophages of orally administered very high dilutions of silica. Eur J Pharmacol (1987) 1.49
Alteration of the response of platelets to surface stimuli by pyrazole compounds. J Exp Med (1967) 1.48
The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood (1998) 1.48
Prevalence and significance of anticardiolipin antibodies in Crohn's disease. Dig Dis Sci (1994) 1.47
Thromboembolism: a manifestation of the response of blood to injury. Circulation (1970) 1.45
Involvement of immunoglobulin E in the secretory processes of alveolar macrophages from asthmatic patients. J Clin Invest (1983) 1.44
Sensitivity and long-term prognostic value of cardiac troponin-I increase shortly after percutaneous transluminal coronary angioplasty. Clin Cardiol (1998) 1.43
Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur J Pharmacol (1983) 1.43
Platelet-surface interactions: relationship to thrombosis and hemostasis. Fed Proc (1967) 1.42
Platelets, thrombosis and drugs. Drugs (1975) 1.40
Effect of ADP-induced shape change on incorporation of 32P into platelet phosphatidic acid and mono-, di- and triphosphatidyl inositol. Br J Haematol (1973) 1.38
Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23,187. J Lab Clin Med (1977) 1.35
Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes. J Immunol (1984) 1.34
Adenosine diphosphate-induced platelet aggregation and myocardial infarction in swine. Lab Invest (1967) 1.33
Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med (1998) 1.31
Comparison of fibrinogen association with normal and thrombasthenic platelets on exposure to ADP or chymotrypsin. Blood (1979) 1.31
Platelet interaction with polymerizing fibrin. J Clin Invest (1972) 1.31
The immune response in NZBxNZW F1 hybrid mice. Clin Exp Immunol (1969) 1.30
Detection and characterization of circulating immune complexes by ultracentrifugation. Technical aspects. J Immunol Methods (1979) 1.30
Changes in 32 p-labelling of platelet phospholipids in response to ADP. Br J Haematol (1972) 1.29
Release of 14C-serotonin during initial platelet changes induced by thrombin, collagen, or A23187. Blood (1977) 1.29
Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost (2005) 1.25
Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils. Immunology (1977) 1.25
Biosynthesis of platelet-activating factor. I. Evidence for an acetyl-transferase activity in murine macrophages. Biochim Biophys Acta (1982) 1.24
In vitro and in vivo functions of thrombin-treated platelets. Thromb Haemost (1976) 1.22
Thrombin generation and fibrin formation following injury to rabbit neointima. Studies of vessel wall reactivity and platelet survival. Lab Invest (1982) 1.22
The human basophil degranulation test as an in vitro method for the diagnosis of allergies. Clin Allergy (1981) 1.21
Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost (2000) 1.21
The effect of platelet age on platelet adherence to collagen. J Clin Invest (1968) 1.20
Changes in 32P-content of phosphatidic acid and the phosphoinositides of rabbit platelets during aggregation induced by collagen or thrombin. Br J Haematol (1974) 1.20
Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis. Proc Natl Acad Sci U S A (1986) 1.20
Platelet economy (platelet survival and turnover). Br J Haematol (1966) 1.20
Rôle of platelets in thrombosis. Thromb Diath Haemorrh Suppl (1966) 1.19
PAF-acether-induced plasma exudation in rat skin is independent of platelets and neutrophils. Microcirc Endothelium Lymphatics (1984) 1.19
Platelet aggregation and release: effects of low concentrations of thrombin or collagen. Am J Physiol (1973) 1.18
HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J Clin Invest (1999) 1.18
Modification of platelet function. Ann N Y Acad Sci (1972) 1.18
Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation (2001) 1.17
Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988. Eur J Pharmacol (1986) 1.17
The effect of plasma proteins on the interaction of platelets with glass surfaces. J Lab Clin Med (1969) 1.16
Clq inhibition of the interaction of collagen with human platelets. J Immunol (1976) 1.16
Localized protein accumulation in the wall of the aorta. Exp Mol Pathol (1967) 1.15
Platelet activating factor (PAF-acether): total synthesis of 1-O-octadecyl 2-O-acetyl sn-glycero-3-phosphoryl choline. FEBS Lett (1980) 1.15
Biosynthetic labelling of platelet activating factor from radioactive acetate by stimulated platelets. Nature (1981) 1.15
Present concepts on the mechanisms of platelet aggregation. Biochem Pharmacol (1981) 1.15
The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol (1998) 1.15
The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin--a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett (2001) 1.15
Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost (1997) 1.14
Arterial thrombosis and protein S deficiency. Thromb Haemost (1989) 1.13
The human platelet ADP receptor activates Gi2 proteins. Biochem J (1995) 1.12
Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest (1975) 1.12
ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood (2000) 1.12
Influence of apyrase on stability of suspensions of washed rabbit platelets. Proc Soc Exp Biol Med (1971) 1.12
Platelet-activating factor (PAF-acether) secretion from platelets: effect of aggregating agents. Br J Haematol (1980) 1.12
Adherence of platelets to a collagen-coated surface: development of a quantitative method. J Lab Clin Med (1973) 1.12
Release of 1-O-alkylglyceryl 3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: chemical ionization mass spectrometry of phospholipids. Proc Natl Acad Sci U S A (1980) 1.11
Experimental hemostasis in normal dogs and dogs with congenital disorders of blood coagulation. Blood (1967) 1.11
Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. Gut (1992) 1.10
Evidence for the involvement of IgE-basophil system in acute serum sickness. Clin Exp Immunol (1976) 1.10
Characterization of CD1e, a third type of CD1 molecule expressed in dendritic cells. J Biol Chem (2000) 1.09
Activation of ADP receptors and platelet function. Thromb Haemost (1997) 1.09